about
The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytesRole of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cellsPotentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization[Neurocardiological acute care]Impaired collateral recruitment and outward remodeling in experimental diabetesNoninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profilingVisualization of coronary wall atherosclerosis in asymptomatic subjects and patients with coronary artery disease using magnetic resonance imaging.Clinical implications of microvascular obstruction and intramyocardial haemorrhage in acute myocardial infarction using cardiovascular magnetic resonance imagingAutocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.VEGF receptor signaling and endothelial function.The BTB-Kelch protein KLEIP controls endothelial migration and sprouting angiogenesis.Growth factor signal transduction defects in the cardiovascular system.Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents.Enhanced external counterpulsation as a new treatment modality for patients with erectile dysfunction.Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome.Sonic hedgehog is a potent chemoattractant for human monocytes: diabetes mellitus inhibits Sonic hedgehog-induced monocyte chemotaxis.VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus.Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification.Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity.New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation.Hh signaling in regeneration of the ischemic heart.Thrombin generation in patients with a first acute myocardial infarction.Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo.MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery.Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.Feed-forward signaling by membrane-bound ligand receptor circuit: the case of NOTCH DELTA-like 4 ligand in endothelial cells.Processes in atherogenesis: complement activation.TGF-β1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus.A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis.Vascular stem and progenitor cells in diabetic complications.Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention.The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability.Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction.Vascular endothelial growth factor-A activates Ca2+ -activated K+ channels in human endothelial cells in culture.Elevated left ventricular end-diastolic pressure favours closure of foramen ovale.Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt.Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes.
P50
Q24303500-B4D5BB56-A961-43AD-8E36-238C8DCA4A3DQ24304277-3036EB5F-CCEF-46D2-AF82-8596672A16F5Q28257153-8CF46C85-A28E-46B0-BCA7-E3FA77CA2517Q28594883-88BFB097-EDB3-489C-B6CA-C65E14308BAAQ33150891-72160B00-B689-42F9-81AA-3D4EF6DFA37FQ33352448-7308914A-19C4-42B4-A8A4-744742D18C7AQ33355010-66AE212E-63C1-4728-B435-896139D4E465Q33712037-E2C7D131-6F86-4145-A421-5F359FEA822CQ34166827-7A5DEA72-902F-442B-8E42-70555D109E0BQ34472952-40D6C0C6-6043-4E66-AF6E-057B466E3368Q34497642-7E019E03-C49C-4847-ABB8-60F6C4D42C05Q34613906-6F1B8E2D-9B03-439B-9261-00850465475DQ36017177-22D7B05A-4016-4750-B8D9-357D07D44D51Q36274545-4371254C-450D-4B67-96AC-56328CBB591EQ36900583-B51AE24F-EAAD-4386-86E1-8E7B347F085BQ37323357-A8FD3C29-F3F1-41A0-96C8-D6E94374D0F7Q37463897-5C209AF3-F3DB-4816-BEEA-9978D62F31A4Q37631627-00D56219-045C-4558-9612-17F1898455A9Q38046512-DBC1F46B-E176-40BC-84D6-384DD229573DQ38304360-65F9FC40-6D4A-4259-A966-90B304BF9828Q38319139-46DEFA10-44A5-4478-ABFB-B862272D543BQ39317210-9C902BF8-98EF-40EA-9800-453D0CC51414Q39807597-A43D95C1-0BDC-4F51-8662-C344B5218FDBQ40372659-D7BA1357-26EB-4C6E-8AC0-C15AD23C5FD6Q40512232-32C226FB-2C9B-4228-928A-48DE848602C3Q40623402-0C5DDEAC-49DF-4EBE-8D1C-9A9A560B9D29Q40659303-634F1D25-D1E7-4A24-BDA0-12B635038166Q41197641-C386668B-A486-4548-BE6D-E6BCD6807E7EQ41550281-C34F3967-82ED-4D93-81DF-E92FD7FB2840Q42486527-80A39434-83C4-44F1-A0FE-CF98EE23BD20Q42674129-46A6A2C5-A847-4D77-AFF6-A70722558A61Q43184158-A9D91D7F-1406-498D-8974-112BD41043E5Q43185883-BE399A52-117B-4761-AEB4-21E28A533E73Q43209084-55B2BF64-4395-41A4-B962-0245263EC541Q43455241-6FF96879-DBE3-42AE-AB1B-8886E4566FD1Q43581575-84B89B25-7287-4EF5-BE42-448925561817Q43597378-A8B80CF1-C119-4EC2-9B60-55B178A3ED1AQ43806613-1DF5186D-CB8E-4FF6-A87B-B37AC4600134Q44085160-1EB3ADD3-2B83-444C-ADCA-808AAE186ECCQ44466905-DD396380-0E5F-4024-9B1C-589FCF0E67F9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Johannes Waltenberger
@ast
Johannes Waltenberger
@en
Johannes Waltenberger
@es
Johannes Waltenberger
@sl
type
label
Johannes Waltenberger
@ast
Johannes Waltenberger
@en
Johannes Waltenberger
@es
Johannes Waltenberger
@sl
prefLabel
Johannes Waltenberger
@ast
Johannes Waltenberger
@en
Johannes Waltenberger
@es
Johannes Waltenberger
@sl
P1053
I-1813-2013
P106
P1153
7005011229
P21
P214
9150686389412540913
P31
P3829
P496
0000-0002-2417-9880
P735
P7859
viaf-9150686389412540913